Home > Compound List > Product Information
Ethionamide_Molecular_structure_CAS_536-33-4)
Click picture or here to close

Ethionamide

Catalog No. DB00609 Name DrugBank
CAS Number 536-33-4 Website http://www.ualberta.ca/
M. F. C8H10N2S Telephone (780) 492-3111
M. W. 166.2434 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 491

SYNONYMS

IUPAC name
2-ethylpyridine-4-carbothioamide
IUPAC Traditional name
ethionamide
Brand Name
Amidazin
Isothin
Amidazine
Aetina
Thianide
Aethionamidum
Ethimide
Etionid
Etionizine
Iridozin
Tianid
Trecator
Tuberoson
Aetiva
Atina
Ethina
Etimid
Etiocidan
Etionizin
Fatoliamid
Iridocin
Isotiamida
Itiocide
Nisotin
Nizotin
Sertinon
Thioniden
Tio-Mid
Tiomid
Trescatyl
Trescazide
Tuberoid
Bayer 5312
Etionizina
Nicotion
Rigenicid
Teberus
Thianid
Thioamide
Thiomid
Trecator-SC
Trekator
Tubenamide
Tubermin
Synonyms
Ethinamide
Etionamida [INN-Spanish]
Etioniamid
ETP
Ethyonomide
Ethionamid prothionamid
ETH
ET
Etionamide [DCIT]
Etionamid
Ethioniamide
Ethylisothiamide
Ethionamidum [INN-Latin]

DATABASE IDS

PubChem CID 2761171
CAS Number 536-33-4
PubChem SID 46506077

PROPERTIES

Hydrophobicity(logP) 0.5
Solubility Practically insoluble

DETAILS

Description (English)
Item Information
Drug Groups approved
Description A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
Indication For use in the treatment of pulmonary and extrapulmonary tuberculosis when other antitubercular drugs have failed.
Pharmacology Ethinamate is bacteriostatic against M. tuberculosis. In a study examining ethionamide resistance, ethionamide administered orally initially decreased the number of culturable Mycobacterium tuberculosis organisms from the lungs of H37Rv infected mice. Drug resistance developed with continued ethionamide monotherapy, but did not occur when mice received ethionamide in combination with streptomycin or isoniazid.
Toxicity Symptoms of overdose include convulsions, nausea, and vomiting.
Affected Organisms
Mycobacteria
Biotransformation Hepatic and extensive. Metabolized to the active metabolite sulfoxide, and several inactive metabolites. The sulphoxide metabolite has been demonstrated to have antimicrobial activity against Mycobacterium tuberculosis.
Absorption Essentially completely absorbed following oral administration and not subjected to any appreciable first pass metabolism. Bioavailability approximately 100%.
Half Life 2 to 3 hours
Protein Binding Approximately 30% bound to proteins.
Elimination Less than 1% of the oral dose is excreted as ethionamide in urine. Ethionamide is extensively metabolized to active and inactive metabolites.
Distribution * 93.5 L [healthy volunteers]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES